News
RNAC
17.59
+6.09%
1.01
Weekly Report: what happened at RNAC last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at RNAC last week (0708-0712)?
Weekly Report · 07/15 10:39
argenx SE: A Post FDA Approval Assessment
Seeking Alpha · 07/10 16:19
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. Is a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases. The company issued to new employees options to purchase an aggregate of 35,198 shares of the Company’s common stock. The options vest on July 1, 2024.
Barchart · 07/08 15:05
Weekly Report: what happened at RNAC last week (0701-0705)?
Weekly Report · 07/08 10:41
Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham
Dow Jones · 07/08 09:47
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Benzinga · 07/08 09:37
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of NIO Inc. Fell 8.5% to $4.4550 on Friday. The company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons. Qualigen Therapeutics, Inc. Shares jumped 120% in today's mid-day session. Macy's, Macy's and Zoomcar Holdings were among the other stocks moving in Friday's session.
Benzinga · 07/05 16:59
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
NASDAQ · 07/04 12:49
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
NASDAQ · 07/03 18:25
Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 07/03 17:45
Cartesian Therapeutics Price Target Cut to $49.00/Share From $54.00 by HC Wainwright & Co.
Dow Jones · 07/03 17:45
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $49
Benzinga · 07/03 17:35
Cartesian Therapeutics Price Target Raised to $43.00/Share From $38.00 by Canaccord Genuity
Dow Jones · 07/03 14:34
Cartesian Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 07/03 14:34
Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43
Benzinga · 07/03 14:23
Buy Rating Affirmed for Cartesian Therapeutics on Descartes-08’s Promising Clinical Trial Results
TipRanks · 07/03 10:18
CARTESIAN THERAPEUTICS INC <RNAC.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $49 FROM $54
Reuters · 07/03 10:10
U.S. RESEARCH ROUNDUP-Ardelyx, Eli Lilly, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Ardelyx, Eli Lilly, Tesla and Waste Management among companies with revised targets. Analysts cut their ratings on several companies on Wednesday. Some analysts raised their targets on some of the companies.
Reuters · 07/03 07:08
CARTESIAN THERAPEUTICS INC <RNAC.O>: CANACCORD GENUITY RAISES TARGET PRICE TO $43 FROM $38
Reuters · 07/03 04:17
More
Webull provides a variety of real-time RNAC stock news. You can receive the latest news about Cartesian through multiple platforms. This information may help you make smarter investment decisions.
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.